Biomea Fusion, Inc.

NASDAQ:BMEA

Biotechnology

Healthcare
$0.74 -2.50%

-$0.03 today

Market cap
$53.18M
Beta
-0.33
P/E (TTM)
-1.9
EPS (TTM)
-$0.62
52W Low $0.87High $2.99

Volume 3.50M

Average 1.52M

BMEA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Biomea Fusion, Inc.NASDAQ: BMEA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $3.65M fell 46.4% year over year, behind the -36.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -25.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.65M+1.4% QoQ
Last fiscal yearDec 2025
$19.33M-25.6% YoY
LTMMar 2026
$16.17M-36.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.4%-100.0%-53.6 pp
1 year-25.6%-100.0%-74.4 pp
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
19.33M USD
Year-over-year change
-25.6%
4-year CAGR
+9.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How BMEA compares with its peers on the latest reported figures

  • BMEA's LTM Mar 2026 selling, general & admin of $16.17M is the 8th highest of the 9 companies compared; the peer median is $21.34M.
  • Its year-over-year change of -36.6% is the 7th highest of 8, against a peer median of -23.4%.
  • Over three fiscal years its annual growth of -2.6% compares with a peer median of +11.7%.
BMEA Competitors Peer median
Selling, General & Admin for BMEA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$35.33M -27.9%-11.7%35.5%
IMUXImmunic, Inc.LTM Mar 2026$23.53M +30.1%+11.7%—
CBUSCibus, Inc.LTM Mar 2026$22.13M -30.7%+41.8%516.4%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$21.4M +37.8%+45.9%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M -23.4%-6.3%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$17.75M +13.9%—451.2%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$17.25M —+15.2%—
BMEABiomea Fusion, Inc.LTM Mar 2026$16.17M -36.6%-2.6%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$15.9M -38.9%-12.9%—
Peer median (excluding BMEA) $21.34M-23.4%+11.7%451.2%

Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00001.41M
Gross Profit0000(1.41M)
Gross Margin—————
Research & Development28M62.71M102.55M118.09M61.98M
Selling, General & Admin13.67M20.92M23.59M25.99M19.33M
Operating Expenses41.67M83.63M126.14M144.07M79.9M
Depreciation & Amortization249K691K1.52M1.75M1.41M
EBITDA(41.32M)(81.14M)(115.74M)(136.68M)(60.39M)
EBITDA Margin—————
Operating Income(41.67M)(83.63M)(126.14M)(144.07M)(81.31M)
Operating Margin—————
Interest Income100K1.81M8.88M5.64M1.86M
Interest Expense00000
Other Income / Expenses100K1.81M8.88M5.64M19.51M
Income Before Tax(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Net Margin—————
EPS (Basic)(1.74)(2.80)(3.44)(3.83)(1.18)
EPS (Diluted)(1.74)(2.80)(3.44)(3.83)(1.18)
Weighted Avg Shares23.86M29.27M34.11M36.11M52.23M
Weighted Avg Shares (Diluted)23.86M29.27M34.11M36.11M52.23M

Biomea Fusion, Inc.

NASDAQ:BMEA

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.